Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.32 |
| ▸ | CACNB3 | P54284 | 1/20 | 0.32 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | BLM | P54132 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5387723 | 0.98 | CACNA2D1 (0.33) | CACNA2D1CACNB3CACNA1CUSP2ALDH1A1 | |
| SCHEMBL5393743 | 0.98 | CACNA2D1 (0.33) | CACNA2D1CACNB3CACNA1CUSP2ALDH1A1 | |
| SCHEMBL7249455 | 0.89 | CACNB3 (0.30) | CACNA2D1CACNB3CACNA1C | |
| SCHEMBL7250237 | 0.89 | CACNB3 (0.30) | CACNA2D1CACNB3CACNA1C | |
| SCHEMBL7250444 | 0.89 | CACNB3 (0.30) | CACNA2D1CACNB3CACNA1C | |
| SCHEMBL7249035 | 0.86 | CACNB3 (0.32) | CACNA2D1CACNB3CACNA1C | |
| SCHEMBL7254824 | 0.85 | CACNB3 (0.31) | CACNA2D1CACNB3CACNA1C | |
| SCHEMBL7479255 | 0.84 | CYP1A2 (0.33) | CACNA2D1CACNB3CACNA1CCYP1A2 | |
| SCHEMBL5405319 | 0.84 | CYP1A2 (0.35) | CACNA2D1CACNB3CACNA1CCYP1A2 | |
| SCHEMBL5405315 | 0.84 | CYP1A2 (0.35) | CACNA2D1CACNB3CACNA1CCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1475371-A1 | 1-SUBSTITUTED-1-AMINOMETHYL-CYCLOALKANE DERIVATIVES (= GABAPENTIN ANALOGUES), THEIR PREPARATION AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | Warner-Lambert Company LLC (US) | 2004-11-10 | — | — | EP | claimed |
| US-20040097405-A1 | Method of treating cartilage damage | SCHRIER DENIS (US) | 2004-05-20 | — | — | US | claimed |
| US-20040006073-A1 | Method of treating attention deficit hyperactivity disorder | DOOLEY DAVID JAMES (US) | 2004-01-08 | — | — | US | claimed |
| US-20030203945-A1 | Heterocyclic derivatives useful as pharmaceutical agents | BLAKEMORE DAVID CLIVE (GB) | 2003-10-30 | — | — | US | claimed |
| US-6518289-B1 | Especially irritable bowel syndrome | PFIZER, INC. | 2003-02-11 | — | — | US | claimed |
| US-20020077342-A1 | Heterocyclic derivatives useful as pharmaceutical agents | WARNER-LAMBERT COMPANY | 2002-06-20 | — | — | US | claimed |
| US-20020072533-A1 | Method of treating cartilage damage | SCHRIER DENIS (US) | 2002-06-13 | — | — | US | claimed |
| WO-2002036118-A2 | HETEROCYCLIC DERIVATIVES USEFUL AS PHARMACEUTICAL AGENTS | WARNER-LAMBERT COMPANY LLC (US) | 2002-05-10 | — | — | WO | claimed |
| EP-1201240-A2 | Heterocyclic derivatives useful as pharmaceutical agents | WARNER-LAMBERT COMPANY (US) | 2002-05-02 | — | — | EP | claimed |
| EP-1199072-A2 | Method of treating cartilage damage | WARNER-LAMBERT COMPANY (US) | 2002-04-24 | — | — | EP | claimed |
| JP-2002508362-A | — | — | 2002-03-19 | — | — | JP | claimed |
| EP-1047678-A1 | 1-SUBSTITUTED-1-AMINOMETHYL-CYCLOALKANE DERIVATIVES (=GABAPENTIN ANALOGUES), THEIR PREPARATION AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | Warner-Lambert Company LLC (US) | 2000-11-02 | — | — | EP | claimed |
| WO-1999031075-A1 | 1-SUBSTITUTED-1-AMINOMETHYL-CYCLOALKANE DERIVATIVES (=GABAPENTIN ANALOGUES), THEIR PREPARATION AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | WARNER-LAMBERT COMPANY (US) | 1999-06-24 | — | — | WO | claimed |
| US-20070293570-A1 | PHARMACEUTICAL USES FOR ALPHA2DELTA LIGANDS | WARNER-LAMBERT COMPANY (US) | 2007-12-20 | — | — | US | disclosed |
| US-20070276039-A1 | PHARMACEUTICAL USES FOR ALPHA2DELTA LIGANDS | WARNER-LAMBERT COMPANY LLC (US) | 2007-11-29 | — | — | US | disclosed |
| US-20070213401-A1 | PHARMACEUTICAL USES FOR ALPHA2DELTA LIGANDS | WARNER-LAMBERT COMPANY LLC (US) | 2007-09-13 | — | — | US | disclosed |
| EP-1199072-A2 | Method of treating cartilage damage | WARNER-LAMBERT COMPANY (US) | 2002-04-24 | — | — | EP | disclosed |
| WO-2001091736-A2 | COMBINATIONS OF AN ENDOTHELIN RECEPTOR ANTAGONIST AND AN ANTIEPILEPTIC COMPOUND HAVING PAIN ALLEVIATING PROPERTIES OR ANALGESIC | WARNER-LAMBERT COMPANY (US) | 2001-12-06 | — | — | WO | disclosed |
| EP-1047678-A1 | 1-SUBSTITUTED-1-AMINOMETHYL-CYCLOALKANE DERIVATIVES (=GABAPENTIN ANALOGUES), THEIR PREPARATION AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | Warner-Lambert Company LLC (US) | 2000-11-02 | — | — | EP | disclosed |
| WO-1999031075-A1 | 1-SUBSTITUTED-1-AMINOMETHYL-CYCLOALKANE DERIVATIVES (=GABAPENTIN ANALOGUES), THEIR PREPARATION AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | WARNER-LAMBERT COMPANY (US) | 1999-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213401-A1 | PHARMACEUTICAL USES FOR ALPHA2DELTA LIGANDS | ADRA2A, ADRA1D, OPRD1 | CACNA2D1 394/4885CACNB3 313/4885CACNA1C 151/4885 |
| US-20070293570-A1 | PHARMACEUTICAL USES FOR ALPHA2DELTA LIGANDS | ADRA2A, ADRA1D, OPRD1 | CACNA2D1 394/4885CACNB3 313/4885CACNA1C 151/4885 |
| US-20020072533-A1 | Method of treating cartilage damage | COL2A1, COL1A1, GABRB1 | CACNA2D1 2778/4885CACNB3 1948/4885CACNA1C 1996/4885 |
| US-20070276039-A1 | PHARMACEUTICAL USES FOR ALPHA2DELTA LIGANDS | ADRA2A, ADRA1D, OPRD1 | CACNA2D1 394/4885CACNB3 313/4885CACNA1C 151/4885 |
| US-20020077342-A1 | Heterocyclic derivatives useful as pharmaceutical agents | CNR1, SUCNR1, CACNA1A | CACNA2D1 192/4885CACNB3 1527/4885CACNA1C 475/4885 |
| US-20030203945-A1 | Heterocyclic derivatives useful as pharmaceutical agents | CNR1, SUCNR1, CACNA1A | CACNA2D1 192/4885CACNB3 1527/4885CACNA1C 475/4885 |
| US-20040097405-A1 | Method of treating cartilage damage | COL2A1, COL1A1, GABRB1 | CACNA2D1 2778/4885CACNB3 1948/4885CACNA1C 1996/4885 |
| US-20040006073-A1 | Method of treating attention deficit hyperactivity disorder | GABRB2, GABBR1, GABBR2 | CACNA2D1 312/4885CACNB3 141/4885CACNA1C 147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.